-- Thursday, February 2 from 10:15-11:45am PT-- General Session II: Castration-Resistant Prostate Cancer -- TreatmentProbably get a PR around 10. We could see some action then. I think if safety were an issue they would not bother waiting for asco.
How would the math/statistics work on the full trial data to get to longer overall survival? Just longer set of data across more patients which could potentially take overall survival higher?
sadly, the trial has had the requisite number of events in the placebo category to determine the average length of life. There is a chance that no time will be added to survival. zytiga added a month, so there is a good chance we may add one also. I am not a statistician, but they should cut the overall survival after they have had the requisite number of deaths in the drug arm to determine the mean survival.
I don't see people selling on good news in this instance. Any good news here would just be a positive sign for more and bigger news in the future. I am watching for a new high today!
Didnt they say they will have some information on fda begining of 2012 also
Bingo, new high and rising.